| abstract |
The invention discloses a bispecific antibody and its use. The first protein functional region and the second protein functional region of the bispecific antibody, the first protein functional region is a protein functional region targeting TIM-3, and the first protein functional region corresponding to targeting TIM-3 The TIM-3 full-length antibody has weak binding activity to rhesus monkey (Macaca) TIM-3, strong binding activity to marmoset (Marmoset) and human TIM-3, and can activate the killing effect of human NK cells on tumor cells. The bispecific antibody can not only retain the activity of activating PBMC (NK) of a single TIM-3 antibody to kill tumor cells, but also can maintain the original activity of another protein functional region, and can achieve the link between two molecules. Activates the activity of T lymphocytes with equal or better (synergistic effect). The bispecific antibody (eg LB141) of the present invention has a superior effect in therapy than PD-1 antibody alone or the combined use of TIM-3 antibody and PD-1 antibody. |